Status:
UNKNOWN
Inflammatory Mediators in Obstructive Sleep Apnoea Syndrome; Mechanisms of Production and the Effect of Long Term Antioxidants Administration
Lead Sponsor:
University of Athens
Conditions:
Obstructive Sleep Apnea Syndrome
Eligibility:
All Genders
Phase:
NA
Brief Summary
Obstructive Sleep Apnea Syndrome (OSAS) is associated with elevated plasma levels of IL-6 and TNF-α, which cannot be accounted for by obesity (Vgontzas et al Sleep Med Rev 2005;9:211-24, Ciftci et al ...
Eligibility Criteria
Inclusion
- Obstructive Sleep Apnea Syndrome diagnosis
Exclusion
- narcolepsy or idiopathic hypersomnia
- chronic obstructive disease,
- neuromuscular or endocrinological disease,
- autoimmune systemic disease,
- psychological disorders,
- use of non steroids antinflammatory drugs,
- use of cortisone drugs,
- recent or concomitant systemic infections
- upper or lower airway infections
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01188005
Start Date
August 1 2010
End Date
October 1 2010
Last Update
August 25 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Critical Care Evangelismos General Hospital
Athens, Attica, Greece